24/7 Market News Snapshot 01 Jul 2024 – Senti Biosciences, Inc. Common Stock (NASDAQ: SNTI)

July 1, 2024 7:09

Press Release

DENVER, Colo., 01 July, 2024 (247marketnews.com) – (Nasdaq:SNTI) are discussed in this article.
Senti Biosciences, Inc. (Nasdaq:SNTI) is making waves in the biotechnology sector, with its Common Stock showing a strong bullish trend in the pre-market session, trading at $0.401 with a notable 45.29% increase from the market open. The stock’s momentum, indicated by a trading volume of 5.1 million shares and previous session close at $0.276, highlights its growth potential. Technical analysis suggests a continuation of this positive trend, making SNTI a stock to watch for investors seeking promising opportunities.

In another significant development, Senti Biosciences has secured an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to advance its innovative cell and gene therapy research efforts. This grant will support the company’s clinical development of SENTI-202, a Logic Gated CAR-NK investigational cell therapy designed for relapsed/refractory hematologic malignancies, particularly AML.

The Phase 1 clinical trial of SENTI-202 is currently in progress, with preliminary efficacy data expected by the end of 2024 and insights into therapy durability anticipated in 2025. Senti Biosciences’ Gene Circuit platform underpins its pioneering research in developing transformative treatments for serious diseases, cementing its position as a leader in the biotechnology landscape.

The CIRM grant underscores the recognition of Senti Biosciences’ commitment to innovation and excellence in advancing novel therapies. Investors and stakeholders are encouraged to follow the progress of SENTI-202 and stay informed about the company’s groundbreaking initiatives by visiting their website for updates. The convergence of a thriving stock performance and substantial research grants positions Senti Biosciences for continued success and advancement in the biotechnology field.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.